PHAXIAM Therapeutics Statistics

Total Valuation

PHAXIAM Therapeutics has a market cap or net worth of GBP 15.14 million. The enterprise value is 17.50 million.

Market Cap	15.14M
Enterprise Value	17.50M

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	9.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.94
EV / Sales	9.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	n/a
Revenue Per Employee	26,694
Profits Per Employee	-273,322
Employee Count	68
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -56.87% in the last 52 weeks. The beta is 1.48, so PHAXIAM Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.48
52-Week Price Change	-56.87%
50-Day Moving Average	2.48
200-Day Moving Average	5.69
Relative Strength Index (RSI)	45.04
Average Volume (20 Days)	21

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PHAXIAM Therapeutics had revenue of GBP 1.82 million and -18.59 million in losses.

Revenue	1.82M
Gross Profit	1.82M
Operating Income	-15.35M
Pretax Income	-18.57M
Net Income	-18.59M
EBITDA	-16.02M
EBIT	-15.35M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-845.73%
Pretax Margin	-1,022.98%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

PHAXIAM Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-122.75%
FCF Yield	n/a

Stock Splits

The last stock split was on September 18, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Sep 18, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a